Dr. John Cush RheumNow
4 years 11 months ago
An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l https://t.co/gaPfj17IrB
Dr. John Cush RheumNow
4 years 11 months ago
Epi-4 studies of 4,376 military service persons shows the prevalence of fibromyalgia = 2.9% predeployment, but was significantly higher in those with postemployment PTSD (10.8%) (not without PTSD-0.8%) but higher if in PTSD RCTs (40%) https://t.co/95tCsMtoyw https://t.co/DpMQqPVfhP
Dr. John Cush RheumNow
4 years 11 months ago
Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/6wOIm8P2gQ
Dr. John Cush RheumNow
4 years 11 months ago
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77 https://t.co/Zv9sSRBSHb
Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast. Let's begin.
While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk.
The latest CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million (23.7%) U.S. adults have arthritis, 25.7 million (43.9%) of whom have AAAL.
Dr. John Cush RheumNow
4 years 11 months ago
Having both Cancer & Systemic sclerosis (SSc) is rare. Study of 1481 SSc pts saw cancer Dx w/in 2, (1.35), 3 (2.1%) & 5 yrs (3.5%;mostly breast, GYN, Heme CA). Higher 2 yr risk w/ topoisomerase I Ab (OR 3.43), U1-RNP (5.54), but not RNA polymerase III) https://t.co/dVuchv8Afv https://t.co/azGmJYifrj
Dr. John Cush RheumNow
4 years 11 months ago
Study of 52 pts with Juvenile Systemic Sclerosis (JSSc) -10% were without skin dz (SSc sine scleroderma). 7 pts reviewed, all had cardiac dz (86 vs 16%; 3 cardiomyopathy, 3PAH), longer Dx delay (20 vs 8 mos), worse outcomes, (42 v 6%) https://t.co/7wGuX8QVBO https://t.co/XdTK7AlPrs
Dr. John Cush RheumNow
4 years 11 months ago
MEDWATCH (FAERS) data on venous thromboembolic (VTE) risk with JAK inhibitors from 2010-2019 https://t.co/oKkTYcRsxL
Dr. John Cush RheumNow
4 years 11 months ago
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/mJ467Nfe8T
Dr. John Cush RheumNow
4 years 11 months ago
Hip fractures represent a major global public health problem - data from ASBMR meeting suggests this is from an aging population and suboptimal OP treatment. Global study shows incr # hip fractures per year, but Post-fracture Rx only at 11-50% https://t.co/LlMDTrH93E https://t.co/ucrPzcnLZh
Dr. John Cush RheumNow
4 years 11 months ago
2125 RA pts in RCTS w/ baricitinib entered a long term F/U study. baricitinib pts had less XRay damage over 5 yrs; 5 yr No Xray progression was 60% on baricitinib 4 mg; 66% baricitinib 4 mg+MTX; vs 41% on just MTX monotherapy. https://t.co/pLuQCDSf6g https://t.co/wFs3G0DrJ7
Dr. John Cush RheumNow
4 years 11 months ago
SLE hospitalized with ARDS from COVID-19 have significantly higher risks of death and poor outcomes (RR=1.7), compared 319 SLE vs 251,800 nonSLE - SLE was more impactful than other comorbidities in such poor outcomes https://t.co/8VJjdOmTbi https://t.co/jYTg6k1QNq
